Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes: A prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta

JACC: Cardiovascular Imaging

Volumn 4, Issue 10, 2011, Pages 1110-1118

  Mizoguchi, Minori ^a   Tahara, Nobuhiro ^a   Tahara, Atsuko ^a   Nitta, Yoshikazu ^a   Kodama, Norihiro ^a   Oba, Toyoharu ^a   Mawatari, Kazutoshi ^a   Yasukawa, Hideo ^a   Kaida, Hayato ^a   Ishibashi, Masatoshi ^a   Hayabuchi, Naofumi ^a   Harada, Haruhito ^a   Ikeda, Hisao ^a   Yamagishi, Sho Ichi ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

atherosclerosis; FDG PET imaging; HDL cholesterol; high sensitivity CRP; pioglitazone; plaque inflammation

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE;

AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CHEMISTRY; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG DOSE TITRATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; IMAGE ANALYSIS; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

AGED; ANTI-INFLAMMATORY AGENTS; AORTIC DISEASES; AORTOGRAPHY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; JAPAN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80054096405     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2011.08.007     Document Type: Article

References (25)

1. S. Aronoff, S. Rosenblatt, S. Braithwaite, J.W. Egan, A.L. Mathisen, R.L. Schneider The Pioglitazone 001 Study Group Pioglitazone hydrochloride monotherapy improves control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled doseresponse study Diabetes Care 23 2000 1605 1611
2. T.A. Kotchen, H.Y. Zhang, S. Reddy, and R.G. Hoffmann Effect of pioglitazone on vascular reactivity in vivo and in vitro Am J Physiol 270 1996 660 666
3. A.A. Parukar, M.L. Pendergrass, R. Granda-Ayala, T.R. Lee, and V.A. Fonseca Nonhypoglycemic effects of thiazolidinediones Ann Intern Med 134 2001 61 71 (Pubitemid 32037344)
4. A. Pftzner, N. Marx, and G. Lbben Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study J Am Coll Cardiol 45 2005 1925 1931 (Pubitemid 40814110)
5. L. Wilhelmsen, J. Betteridge, K. Birkeland PROactive Investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
6. R. Wilcox, M.G. Bousser, D.J. Betteridge PROactive Investigators Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) Stroke 38 2007 865 873 (Pubitemid 46568445)
7. E. Erdmann, J.A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I.K. Moules, A.M. Skene PROactive Investigators The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study J Am Coll Cardiol 49 2007 1772 1780 (Pubitemid 46629127)
8. T. Mazzone, P.M. Meyer, and S.B. Feinstein Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2006 2572 2581 (Pubitemid 44903861)
9. S.E. Nissen, S.J. Nicholls, K. Wolski PERISCOPE Investigators Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573 (Pubitemid 351482795)
10. C.L. Lendon, M.J. Davies, G.V. Born, and P.D. Richardson Atherosclerotic plaque caps are locally weakened when macrophages density is increased Atherosclerosis 87 1991 87 90
11. A.C. van der Wal, A.E. Becker, C.M. van der Loos, and P.K. Das Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology Circulation 89 1994 36 44 (Pubitemid 24026469)
12. P. Libby, Y.J. Geng, and M. Aikawa Macrophages and atherosclerotic plaque stability Curr Opin Lipidol 7 1996 330 335 (Pubitemid 26372454)
13. R. Virmani, F.D. Kolodgie, A.P. Burke, A. Farb, and S.M. Schwartz Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions Arterioscler Thromb Vasc Biol 20 2000 1262 1275 (Pubitemid 30262927)
14. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874 (Pubitemid 36019640)
15. M.E. Rosenfeld Leukocyte recruitment into developing atherosclerotic lesions: the complex interaction between multiple molecules keeps getting more complex Arterioscler Thromb Vasc Biol 22 2002 361 363 (Pubitemid 34218739)
16. N. Tahara, T. Imaizumi, R. Virmani, and J. Narula Clinical feasibility of molecular imaging of plaque inflammation in atherosclerosis J Nucl Med 50 2009 331 334
17. N. Tahara, H. Kai, and M. Ishibashi Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography J Am Coll Cardiol 48 2006 1825 1831 (Pubitemid 44648621)
18. N. Tahara, H. Kai, and S. Yamagishi Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome J Am Coll Cardiol 49 2007 1533 1539 (Pubitemid 46517964)
19. N. Tahara, H. Kai, and H. Nakaura The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography Eur Heart J 28 2007 2243 2248 (Pubitemid 47428937)
20. J.H. Rudd, J. Narula, and H.W. Strauss Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol 55 2010 2527 2535
21. J.M. Laurberg, A.K. Olsen, and S.B. Hansen Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation Atherosclerosis 192 2007 275 282 (Pubitemid 46726328)
22. J.H. Rudd, E.A. Warburton, and T.D. Fryer Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography Circulation 105 2002 2708 2711 (Pubitemid 34615139)
23. A. Tawakol, R.Q. Migrino, and G.G. Bashian In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients J Am Coll Cardiol 48 2006 1818 1824 (Pubitemid 44648622)
24. AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial Am Heart J 161 2011 538 543
25. Actos (pioglitazone hydrochloride) 2008 Takeda Pharmaceuticals America Deerfield, IL [product label]